lifitegrast 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
integrin antagonists 5174 1025967-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lifitegrast
  • SAR 1118-023
  • SAR 1118
  • SAR-1118
  • xiidra
a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues
  • Molecular weight: 615.48
  • Formula: C29H24Cl2N2O7S
  • CLOGP: 2.28
  • LIPINSKI: 1
  • HAC: 9
  • HDO: 2
  • TPSA: 133.99
  • ALOGS: -5.03
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 11, 2016 FDA SHIRE DEV LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site pain 2908.66 31.32 400 6985 504 63481133
Instillation site reaction 2281.73 31.32 300 7085 182 63481455
Eye irritation 1758.07 31.32 424 6961 21547 63460090
Vision blurred 1337.25 31.32 471 6914 91453 63390184
Dysgeusia 783.01 31.32 267 7118 46443 63435194
Instillation site irritation 594.15 31.32 78 7307 44 63481593
Instillation site pruritus 559.78 31.32 71 7314 14 63481623
Instillation site erythema 514.12 31.32 67 7318 32 63481605
Eye pain 487.29 31.32 173 7212 33681 63447956
Instillation site lacrimation 432.48 31.32 54 7331 3 63481634
Ocular hyperaemia 340.80 31.32 123 7262 25021 63456616
Lacrimation increased 294.87 31.32 105 7280 20526 63461111
Dry eye 279.90 31.32 122 7263 40639 63440998
Eye discharge 271.41 31.32 74 7311 5989 63475648
Instillation site discharge 260.52 31.32 33 7352 6 63481631
Instillation site swelling 217.65 31.32 27 7358 0 63481637
Product container issue 207.99 31.32 47 7338 1746 63479891
Eye pruritus 200.31 31.32 77 7308 18594 63463043
Product quality issue 169.81 31.32 83 7302 35782 63445855
Instillation site discomfort 169.28 31.32 21 7364 0 63481637
Ocular discomfort 149.81 31.32 43 7342 4190 63477447
Visual impairment 144.76 31.32 101 7284 84345 63397292
Product use complaint 138.22 31.32 36 7349 2438 63479199
Eye disorder 111.83 31.32 54 7331 22631 63459006
Instillation site dryness 101.30 31.32 13 7372 4 63481633
Eyelid margin crusting 91.96 31.32 22 7363 1050 63480587
Eye swelling 88.78 31.32 47 7338 23871 63457766
Instillation site inflammation 88.66 31.32 11 7374 0 63481637
Product packaging quantity issue 86.78 31.32 22 7363 1337 63480300
Foreign body sensation in eyes 84.91 31.32 24 7361 2210 63479427
Instillation site foreign body sensation 77.98 31.32 10 7375 3 63481634
Instillation site burn 72.54 31.32 9 7376 0 63481637
Taste disorder 71.81 31.32 34 7351 13628 63468009
Inappropriate schedule of product administration 68.79 31.32 72 7313 103893 63377744
Superficial injury of eye 66.43 31.32 13 7372 236 63481401
Instillation site hypersensitivity 56.42 31.32 7 7378 0 63481637
Product taste abnormal 55.65 31.32 17 7368 2050 63479587
Madarosis 48.99 31.32 17 7368 3064 63478573
Instillation site paraesthesia 48.36 31.32 6 7379 0 63481637
Product dose omission issue 47.46 31.32 92 7293 234221 63247416
Swelling of eyelid 44.78 31.32 16 7369 3140 63478497
Asthenopia 37.56 31.32 13 7372 2324 63479313
Erythema of eyelid 33.99 31.32 12 7373 2274 63479363
Product dispensing issue 33.83 31.32 7 7378 170 63481467
Product delivery mechanism issue 33.81 31.32 8 7377 364 63481273
Product storage error 33.07 31.32 21 7364 14935 63466702
Product packaging issue 32.81 31.32 10 7375 1196 63480441
Product label issue 32.75 31.32 9 7376 747 63480890
Photophobia 32.28 31.32 22 7363 17613 63464024
Instillation site haemorrhage 32.24 31.32 4 7381 0 63481637

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site reaction 607.32 98.13 67 1126 19 34955719
Vision blurred 545.29 98.13 150 1043 45813 34909925
Instillation site pain 509.57 98.13 58 1135 40 34955698
Eye irritation 458.47 98.13 93 1100 7468 34948270
Lacrimation increased 138.47 98.13 36 1157 8446 34947292
Instillation site lacrimation 130.08 98.13 14 1179 0 34955738
Eye pain 108.96 98.13 33 1160 13429 34942309
Instillation site erythema 98.78 98.13 11 1182 4 34955734

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Instillation site pain 2341.79 39.70 292 3752 431 79739913
Instillation site reaction 1837.58 39.70 218 3826 137 79740207
Vision blurred 821.95 39.70 275 3769 105623 79634721
Eye irritation 558.50 39.70 142 3902 20539 79719805
Instillation site irritation 421.91 39.70 50 3994 29 79740315
Instillation site erythema 416.35 39.70 49 3995 24 79740320
Dysgeusia 411.96 39.70 141 3903 57036 79683308
Instillation site pruritus 365.42 39.70 42 4002 9 79740335
Instillation site lacrimation 305.74 39.70 35 4009 6 79740338
Eye pain 192.01 39.70 72 3972 37506 79702838
Ocular hyperaemia 188.84 39.70 66 3978 28140 79712204
Instillation site swelling 186.73 39.70 21 4023 0 79740344
Eye discharge 160.32 39.70 41 4003 5993 79734351
Instillation site discomfort 160.05 39.70 18 4026 0 79740344
Instillation site discharge 160.05 39.70 18 4026 0 79740344
Product quality issue 155.22 39.70 60 3984 33880 79706464
Lacrimation increased 148.12 39.70 52 3992 22425 79717919
Product container issue 106.10 39.70 22 4022 1269 79739075
Eye pruritus 89.15 39.70 35 4009 20535 79719809
Instillation site burn 80.02 39.70 9 4035 0 79740344
Visual impairment 73.45 39.70 50 3994 92081 79648263
Instillation site inflammation 71.12 39.70 8 4036 0 79740344
Product dose omission issue 66.76 39.70 72 3972 247465 79492879
Instillation site foreign body sensation 62.23 39.70 7 4037 0 79740344
Eye swelling 58.49 39.70 28 4016 26440 79713904
Instillation site dryness 50.91 39.70 6 4038 3 79740341
Foreign body sensation in eyes 49.24 39.70 13 4031 2144 79738200
Inappropriate schedule of product administration 49.07 39.70 46 3998 133582 79606762
Product use complaint 47.43 39.70 13 4031 2470 79737874
Dry eye 47.00 39.70 27 4017 36904 79703440
Instillation site paraesthesia 44.45 39.70 5 4039 0 79740344
Ulcerative keratitis 42.34 39.70 13 4031 3676 79736668
Eyelid margin crusting 42.33 39.70 10 4034 1049 79739295
Eye disorder 40.57 39.70 21 4023 23391 79716953
Product packaging quantity issue 39.93 39.70 10 4034 1339 79739005

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01XA25 SENSORY ORGANS
OPHTHALMOLOGICALS
OTHER OPHTHALMOLOGICALS
Other ophthalmologicals
MeSH PA D009883 Ophthalmic Solutions
MeSH PA D019999 Pharmaceutical Solutions
FDA MoA N0000192700 Lymphocyte Function-Associated Antigen-1 Antagonists
FDA EPC N0000192701 Lymphocyte Function-Associated Antigen-1 Antagonist
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:133024 lymphocyte function-associated antigen-1 antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tear film insufficiency indication 46152009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.42 acidic
pKa2 12.3 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 10124000 Nov. 5, 2024 TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 7745460 Nov. 5, 2024 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 7790743 Nov. 5, 2024 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8592450 May 17, 2026 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8367701 April 15, 2029 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 9447077 April 15, 2029 TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5% XIIDRA NOVARTIS N208073 July 11, 2016 RX SOLUTION/DROPS OPHTHALMIC 8168655 May 9, 2029 TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Integrin alpha-L/beta-2 Adhesion ANTAGONIST IC50 8.05 SCIENTIFIC LITERATURE DRUG LABEL
Intercellular adhesion molecule 1 Antibody IC50 8.53 CHEMBL

External reference:

IDSource
038E5L962W UNII
D10374 KEGG_DRUG
4035938 VANDF
C3713860 UMLSCUI
CHEBI:133023 CHEBI
CHEMBL2048028 ChEMBL_ID
11965427 PUBCHEM_CID
DB11611 DRUGBANK_ID
CHEMBL2048409 ChEMBL_ID
9584 INN_ID
7533 IUPHAR_LIGAND_ID
1801820 RXNORM
243704 MMSL
31873 MMSL
016935 NDDF
720489009 SNOMEDCT_US
763569006 SNOMEDCT_US
C575157 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 0078-0911 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 24 sections
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 0078-0911 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 24 sections
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 0078-0911 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 24 sections
Xiidra HUMAN PRESCRIPTION DRUG LABEL 1 54092-606 SOLUTION/ DROPS 50 mg OPHTHALMIC NDA 23 sections